이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD)

2026년 10월 30일 업데이트: Jing Chen, University of Texas Southwestern Medical Center

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)

This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease (CKD) and existing coronary artery calcification. Sixty participants will be randomized 1:1 to received LoDoCo plus usual care or usual care lone and followed for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression measured by ECG-gates noncontrast cardiac computed tomography (CT). Exploratory outcomes include valvular calcification, bone mineral density, inflammatory, vascular, and miner-bone biomarkers, cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures, kidney biomarkers, and participant-reported measures of treatment acceptability, adherence, and adverse effects.

연구 개요

상세 설명

The investigators will conduct a randomized, open-label, outcome-blinded, clinical trial in 60 adults with chronic kidney disease (CKD) and existing coronary artery calcification (CAC) Agatston scores of ≥100-1000. Participants will be randomized 1:1 to receive low-dose Colchicine (LoDoCo) plus usual care or usual care alone for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression over 24 months. CAC will be assessed by ECG-gated noncontrast cardiac computed tomography (CT). Outcomes will include Agatston score and calcium volume. The study will estimate variance, baseline-to-follow-up correlations, and other parameters needed to inform future sample size, treatment duration, and endpoint selection.

Exploratory objectives include evaluating the effects of LoDoCo on aortic valve and mitral annular calcification, CT-derived vertebral bone mineral density, inflammatory biomarkers, vascular calcification biomarkers, and miner-bone metabolism biomarkers. Additional exploratory analyses will examine cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures including ankle-brachial index (ABI) and toe-brachial index (TBI), and kidney outcomes including albumin-creatine ratio (uACR) and estimated glomerular filtration rate (eGFR).

Participant experience with LoDoCo will also be evaluated through assessment of treatment acceptability, adherence, adverse effects, and barriers and facilitators to study participation and retention.

Participants will be followed at baseline, 6 months, 12 months, 18 months, and 24 months for data collection. Participants assigned to the intervention group will undergo additional safety monitoring, including laboratory assessments, throughout the study period.

연구 유형

중재적

등록 (추정된)

60

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

30년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Men and women aged 30-<70 years of all race/ethnicity groups
  • Chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate (eGFR) 30 to <60 ml/min/1.73m2) or eGFR ≥60 and Urine albumin-to-creatinine ratio (uACR) ≥ 30 mg/g
  • Cardiac artery calcification (CAC) Agatston score ≥100-1000
  • Ability to provide informed consent.

Exclusion Criteria:

  • Current Colchicine therapy
  • Hepatic disease
  • Established peripheral arterial disease (PAD) defined by self-report or ICD-10 codes
  • Congestive heart failure classified as New York Heart Association (NYHA) Functional class III or IV
  • Uncontrolled atrial fibrillation with resting heart rate > 100 beats/min
  • Dementia defined by self-report or ICD-10 codes (F01-F03)
  • Alzheimer's disease defined by self-report or ICD-10 codes (G30)
  • Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.
  • Immunosuppression, including the use of immunosuppressive medications
  • Current use of chemotherapy drugs or active cancer
  • Pregnancy/breastfeeding
  • Hospitalized within the past 6 months
  • Allergic/intolerance to colchicine
  • Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir)
  • Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)
  • Human immunodeficiency virus (HIV) infection
  • Gout attack ≥ 1 time per year
  • Severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
  • eGFR <30 ml/min/1.73m2
  • White blood cell count (WBC) <3.0 x10^9/L
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
  • Total bilirubin >2 x ULN
  • Glucose >300mg/dL
  • Uses recreational drugs
  • Participant in other conflict clinical trial
  • Unable to complete the study measurements
  • Unable to undergo to computed tomography (CT)
  • Unsafe to participate in this study per investigator's judgement
  • Unable to read and speak English or Spanish

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Low-Dose Colchicine (LoDoCo)

Participants will receive low-dose Colchicine (LoDoCo) in addition to usual care.

Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.

다른 이름들:
  • 로도코

Participants will receive usual care according to standard clinical practice and treating physician discretion.

활성 비교기: Usual Care

Participants will receive usual care alone.

Participants will receive usual care according to standard clinical practice and treating physician discretion.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Coronary Artery Calcification Agatston Scores
기간: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Coronary artery calcification will be quantified using the Coronary Artery Calcium (CAC) Agatston Score. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Change in Coronary Artery Calcification Volume Scores
기간: Baseline, 12 months, 24 months

Change in Coronary Artery Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months

기타 결과 측정

결과 측정
측정값 설명
기간
Exploratory: Change in Aortic Valve Calcification Agatston Scores
기간: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Aortic valve calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the aortic valve. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Aortic Valve Calcification Volume Scores
기간: Baseline, 12 months, 24 months

Change in Aortic Valve Calcification volume (mm3) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Agatston Scores
기간: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Mitral annular calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the mitral valve annulus. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Volume Scores
기간: Baseline, 12 months, 24 months

Change in Mitral Annular Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Vertebral Bone Mineral Density (BMD)
기간: Baseline, 12 months, 24 months

Change in vertebral BMD (mg/cm³) will be measured from ECG-gated non-contrast computer tomography (CT) using validated CT-based densitometry methods. BMD will be quantified within the vertebral bodies. Vertebral MBD values range from <80mg/cm³ (very low), 80-120mg/cm³ (low), and >120 mg/cm³ (normal). Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in C-Reactive Protein (CRP) Levels
기간: Baseline, 12 months, 24 months

Circulating CRP (mg/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-1 beta (IL-1β) Levels
기간: Baseline, 12 months, 24 months

Circulating IL-1β levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-6 (IL-6) Levels
기간: Baseline, 12 months, 18 months

Circulating IL-6 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 18 months
Exploratory: Change in Interleukin-18 (IL-18) Levels
기간: Baseline, 12 months, 24 months

Circulating IL-18 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tumor Necrosis Factor alpha
기간: Baseline, 12 months, 24 months

Circulating TNF-a levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-17 (IL-17) Levels
기간: Baseline, 12 months, 24 months

Circulating IL-17 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Monocyte Chemoattractant Protein-1 (MCP-1) levels
기간: Baseline, 12 months, 24 months

Circulating MCP-1 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Klotho Levels
기간: Baseline, 12 months, 24 months

Circulating klotho levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fetuin A Levels
기간: Baseline, 12 months, 24 months

Circulating fetuin A levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Osteopontin Levels
기간: Baseline, 12 months, 24 months

Circulating osteopontin levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-2 (BMP-2) Levels
기간: Baseline, 12 months, 24 months

Circulating BMP-2 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-4 (BMP-4) Levels
기간: Baseline, 12 months, 24 months

Circulating BMP-4 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-7 (BMP-7) Levels
기간: Baseline, 12 months, 24 months

Circulating BMP-7 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Phosphate levels
기간: Baseline, 12 months, 24 months

Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Calcium Levels
기간: Baseline, 12 months, 24 months

Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Parathyroid Hormone (PTH) levels
기간: Baseline, 12 months, 24 months

Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone-Specific Alkaline Phosphatase (BSAP) Levels
기간: Baseline, 12 months, 24 months

Circulating serum BSAP levels (ug/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fibroblast Growth Factor 23 (FGF23) Levels
기간: Baseline, 12 months, 24 months

Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Wnt Inhibitory Factor-1 Levels
기간: Baseline, 12 months, 24 months

Circulating Wnt Inhibitory Factor-1 (pg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Intact N-Terminal Propeptide of Type I Procollagen (P1NP) Levels
기간: Baseline, 12 months, 24 months

Circulating P1NP levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Sclerostin Levels
기간: Baseline, 12 months, 24 months

Circulating sclerostin levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) Levels
기간: Baseline, 12 months, 24 months

Circulating TRAP-5b levels (U/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in National Institutes of Health (NIH) Toolbox Fluid Cognition Composite Standard Score
기간: Baseline, 12 months, 24 months

The NIH Toolbox Fluid Cognition Composite score assesses cognitive functions involved in processing and responding to new information, including attention, executive function, episodic memory, processing speed, and working memory. The age-adjusted Fluid Cognition Composite Standard Score is derived from participant performance on NIH Toolbox cognitive assessments and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Scores of 70 or lower indicate significant impairment, scores around 85 are below average, scores around 100 are average, scores around 115 are above average, and scores around 130 are superior. Higher scores indicate better cognitive performance.

Baseline, 12 months, 24 months
Exploratory: Change in Executive Function
기간: Baseline, 12 months, 24 months

Executive function will be assessed using the NIH Toolbox Dimensional Change Card Sort Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Attention/Inhibitory Control
기간: Baseline, 12 months, 24 months

Attention and inhibitory control will be assessed using the NIH Toolbox Flanker Inhibitory Control Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better attention and inhibitory control.

Baseline, 12 months, 24 months
Exploratory: Change in Processing Speed
기간: Baseline, 12 months, 24 months

Processing speed will be assessed using the NIH Toolbox Pattern Comparison Processing Speed test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better processing speed.

Baseline, 12 months, 24 months
Exploratory: Change in Working Memory
기간: Baseline, 12 months, 24 months

Working memory will be assessed using the NIH Toolbox List Sorting Working Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better working memory.

Baseline, 12 months, 24 months
Exploratory: Change in Episodic Memory
기간: Baseline, 12 months, 24 months

Episodic memory will be assessed using the NIH Toolbox Picture Sequence Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better episodic memory.

Baseline, 12 months, 24 months
Exploratory: Change in Language/Vocabulary
기간: Baseline, 12 months, 24 months

Language/Vocabulary will be assessed using the NIH Toolbox Picture Vocabulary Test and Oral Reading Recognition tests. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better language ability.

Baseline, 12 months, 24 months
Exploratory: Change in Southwestern Assessment of Processing Speed (SWAPS) Score
기간: Baseline, 12 months, 24 months

The SWAPS will be used to assess processing speed. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better processing speed performance.

Baseline, 12 months, 24 months
Exploratory: Change in Texas Card Sorting Test (TCST) Score
기간: Baseline, 12 months, 24 months

The TCST will be used to assess executive functioning, including cognitive flexibility and concept formation. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Phosphorylated tau 217 (p-tau217) levels
기간: Baseline, 12 months, 24 months

Circulating p-tau217 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Amyloid-beta 42/40 ratio (Aβ42/40) Levels
기간: Baseline, 12 months, 24 months

Circulating Aβ42 and Aβ40 levels (pg/mL) will be measured using standard clinical laboratory assays and the Aβ42/40 ratio calculated from these measurements and reported as a unitless ratio.

Baseline, 12 months, 24 months
Exploratory: Change in Ankle-Brachial Index (ABI)
기간: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). ABI values range from ≤0.90 (Peripheral artery disease), 0.91-0.99 (borderline), 1.00-1.40 (normal).ABI values >1.40 indicate non-compressible arteries, suggestive of arterial stiffness or medial calcification. Both ABI values ≤0.90 and >1.40 are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Toe-Brachial Index (TBI)
기간: Baseline, 12 months, 24 months

TBI will be measured using semi-automated validated device (simpleABI-600CL). TBI values range from ≥0.70 (normal), 0.64-0.69 (borderline), and <0.40-0.50 (severe distal arterial disease/critical ischemia range). TBI values <0.70 is a commonly used threshold suggestive of peripheral artery disease. Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Percentage of Participants with Ankle-Brachial Index (ABI) ≤0.9 or >1.4
기간: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). The percentage (%) of participants with an ABI ≤0.9, indicative of peripheral arterial disease, or an ABI >1.4, indicative of non-compressible arteries suggestive of arterial stiffness or medial calcification will be determined. Higher percentages indicate a greater proportion of participants with abnormal ABI findings.

Baseline, 12 months, 24 months
Exploratory: Change in Urine Albumin-to-Creatine Ratio (uACR)
기간: Baseline, 12 months, 24 months

Circulating urinary albumin and creatine levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Estimated Glomerular Filtration Rate (eGFR)
기간: Baseline, 12 months, 24 months

eGFR values (mL/min/1.73m2) will be calculated using the NKF-ASN CKD-Epi refit formula.

Baseline, 12 months, 24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Jing Chen, MD, University of Texas

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 30일

기본 완료 (추정된)

2029년 5월 1일

연구 완료 (추정된)

2029년 5월 1일

연구 등록 날짜

최초 제출

2026년 6월 11일

QC 기준을 충족하는 최초 제출

2026년 6월 11일

처음 게시됨 (실제)

2026년 6월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 30일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

IRB approval is required before sharing IPD.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다